Table 1 Characteristics of enrolled studies in diffuse large B-cell lymphoma
author | country | year | cut-off | cases | antibody | Follow-up (month) | therapeutic regimen | HR (95%CI) of OS | HR (95%CI) of PFS | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
PD-L1+/− | clone | dilution | source | ||||||||
Kiyasu J | Japan | 2015 | 0.3 | 34/239 | EPR1161 | 1:200 | Dako | 60 | 80%RCHOP/CHOP-like | 1.809 (1.051–3.112) | NA |
Xing W | America | 2016 | 0.3 | 14/72 | E1L3N | NA | Cell Signaling | 21 (0.067–175) | RCHOP | 2.418 (1.031–5.670) | 2.130 (1.050–4.330) |
Kwon D | Korea | 2016 | 0.1 | 77/49 | E1L3N | NA | Cell Signaling | 52 (16–165) | RCHOP | 0.430 (0.152–1.217) | NA |
Dong L | China | 2016 | 0.05 | 54/46 | ab153991 | 1:200 | NA | 52.4 (1.5–89.1) | CHOP/CHOP-like+ 39%R | 4.740 (1.097–20.477) | NA |
Four M | France | 2016 | 0.05 | 12/20 | SP142 | NA | Ventana | 17 (1–78) | chemotherapy and/or radiotherapy | 7.7 (1.6–37.2) | 1.7 (0.67–4.28) |
Bledsoe JR | America | 2016 | 0.25 | 20/26 | E1L3N | 1:200 | Cell Signaling | 78 | RCHOP | 0.29 (0.06–1.25) | 0.19 (0.04–0.83) |
Hu LY | China | 2017 | 0.05 | 100/104 | NA | 1:50 | Cell Signaling | 52 (1–114) | RCHOP+ 26.7%RT | 4.055 (1.610–10.230) | 1.584 (1.000–2.510) |
Fang X | China | 2017 | 0.1 | 20/54 | SP142 | ready to use | ZSGB-BIO | 2.4–86.4 | CHOP/CHOP-like+ 55.2%R | 2.547 (0.964–6.730) | NA |
Liu Y | China | 2018 | 0.3 | 11/81 | SP142 | NA | NA | 58 (1–78) | RCHOP | 4.63 (1.53–13.99) | NA |
Ishikawa E | Japan | 2018 | 0.05 | 3/48 | SP142 | NA | NA | 42 (3.5–150) | 86.4%RCHOP | 5.72 (1.50–21.8) | NA |
Sun C | China | 2018 | 0.5 | 34/253 | 22C3 | NA | Dako | 76 | CHOP/CHOP-like+ 53.7%R | 1.494 (0.868–2.571) | NA |
Kwon HJ | Korea | 2018 | 0.3 | 23/84 | E1L3N | 1:100 | Cell Signaling | NA | 86.9%RCHOP/CHOP-like | 1.21 (0.15–9.98) | 2.21 (0.59–8.27) |
Shi YF | China | 2018 | 0.3 | 21/104 | SP142 | 1:100 | Ventana | 25.7 (0.8–131.1) | 58.1%RCHOP/CHOP-like;29.7%surgery | NA | 0.379 (0.149–0.962) |